Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

419.89 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum?
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, charts show bullish trend. 
Via Benzinga
Stocks Pause Gains As Treasury Yields Rise: What's Driving Markets Monday?
Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services... 
Via Benzinga
Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
 
Via Benzinga
Earnings Scheduled For May 5, 2025
 
Via Benzinga
Earnings Outlook For Vertex Pharmaceuticals
 
Via Benzinga
Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now
Now may be a smart time to buy small stakes in these fundamentally robust companies. 
Via The Motley Fool
Topics Artificial Intelligence Economy
3 No-Brainer Stocks to Buy in May
Via The Motley Fool
5 Growth Stocks to Buy in May and Go Away
Via The Motley Fool
Topics Artificial Intelligence Government World Trade
Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
S&P Global, Berkshire Hathaway, CME Group And A Health Care Stock: CNBC's 'Final Trades'
 
Via Benzinga
Topics Stocks
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential 
Via Chartmill
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Via The Motley Fool
Topics Artificial Intelligence Energy
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Via The Motley Fool
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Via The Motley Fool
Topics Government
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts
 
Via Benzinga
Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right
Via The Motley Fool
Topics Economy Government World Trade
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and potential upside surprises. 
Via Benzinga
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next
Via The Motley Fool
Topics Government World Trade
Peering Into Vertex Pharmaceuticals's Recent Short Interest
 
Via Benzinga
As The Nasdaq 100 Index Crashes, Is It Safe To Buy The Dip?
The Nasdaq 100 Index remains under pressure after forming a death cross pattern a few weeks ago. It has retreated to $18,257, down by over 17.8% from its highest point this year. 
Via Talk Markets
Topics Stocks / Equities
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'
CrowdStrike has expanded its partnership with Google Cloud to enable end-to-end security for AI innovation. 
Via Benzinga
Topics Artificial Intelligence
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.
Via The Motley Fool
Topics Economy Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.